The future of sterile QA in biotech manufacturing will depend on how well quality teams evaluate changing processes and the evidence behind them. Technologies that reduce exposure or provide earlier information can help manufacturers, but each brings questions about suitability, control and human judgement. Our view is that QA needs to influence these decisions
ESG in pharmaceutical quality assurance requires careful judgement about where quality responsibilities meet wider business expectations. Environmental, social and governance considerations can affect supplier selection, operational improvements and the evidence requested by customers. QA teams have useful skills to contribute, but their role needs to be defined alongside sustainability, procurement, engineering and legal colleagues.
Annex 1 contamination control now demands sustained attention beyond the initial implementation project. The revised EU GMP Annex 1 came into operation on 25 August 2023, with paragraph 8.123 following on 25 August 2024. For manufacturers in 2026, the useful question is whether the controls established during implementation still reflect the facility, its processes
A pharmaceutical quality decision is only as reliable as the evidence behind it. A result may meet its specification, but QA also needs to understand how that result was generated, whether it was changed and whether the complete record supports the conclusion. In 2026, pharmaceutical audit trails deserve attention because digital workflows can make
